奥锐转债

Search documents
奥锐特药业股份有限公司首次公开发行部分限售股上市流通公告
Shang Hai Zheng Quan Bao· 2025-09-12 20:26
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:605116 证券简称:奥锐特 公告编号:2025-066 债券代码:111021 债券简称:奥锐转债 奥锐特药业股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ● 本次股票上市类型为首发股份;股票认购方式为网下,上市股数为6,606,000股。 (一)2022年限制性股票激励计划授予增加总股本 2022年10月17日,公司召开2022年第一次临时股东大会,审议并通过了《关于公司〈2022年限制性股票 激励计划(草案)〉及其摘要的议案》《关于公司〈2022年限制性股票激励计划实施考核管理办法〉的 议案》《关于提请公司股东大会授权董事会办理2022年限制性股票激励计划有关事项的议案》等议案, 同意公司采用限制性股票作为激励工具,向激励对象定向发行公司股票。本次授予的5,195,000股限制性 股票已于2022年11月7日在中国证券登记结算有限责任公司上海分公司完成授予登记,并取得其出具的 《证券变更登 ...
奥锐特药业股份有限公司关于部分高管减持股份计划公告
Shang Hai Zheng Quan Bao· 2025-08-04 18:59
Core Viewpoint - The announcement details a share reduction plan by a senior executive of Aorite Pharmaceutical Co., Ltd. due to personal financial needs, involving a maximum reduction of 62,500 shares, which is 0.02% of the total share capital [2][3]. Group 1: Executive Shareholding Information - As of the announcement date, the total number of shares for Aorite Pharmaceutical is 406,195,234, with the executive Zhao Zhenping holding 250,000 shares, representing 0.06% of the total share capital [2]. Group 2: Reduction Plan Details - The executive plans to reduce shares through centralized bidding within three months after the announcement, starting 15 trading days later, with a maximum of 62,500 shares to be sold [3]. - The reduction will not exceed 25% of the executive's total shareholding, and any changes in share capital due to dividends or other corporate actions will adjust the reduction quantity accordingly [3]. Group 3: Other Relevant Information - The executive has no concerted actions with other shareholders and has made prior commitments regarding shareholding and reduction methods [4][6]. - The company will monitor the reduction plan and comply with relevant regulations, ensuring timely disclosure of any developments [9][17].
股市必读:奥锐特(605116)8月1日主力资金净流出571.48万元,占总成交额5.0%
Sou Hu Cai Jing· 2025-08-03 21:52
截至2025年8月1日收盘,奥锐特(605116)报收于23.96元,下跌0.58%,换手率1.19%,成交量4.75万手, 成交额1.14亿元。 当日关注点 交易信息汇总 公司公告汇总 奥锐特药业股份有限公司发布了关于使用部分闲置募集资金进行现金管理到期赎回的公告。主要内容包 括:- 证券代码:605116,证券简称:奥锐特,公告编号:2025-052,债券代码:111021,债券简称: 奥锐转债。- 公司及子公司获准使用不超过人民币3亿元的闲置募集资金进行现金管理,额度可滚动使 用,有效期自第三届董事会第八次会议审议通过之日起12个月内,并授权管理层决策,财务部负责实 施。- 2025年6月30日,公司用4000万元购买了兴业银行企业金融人民币结构性存款产品,产品期限为 2025年7月1日至2025年7月31日,现已赎回,本金4000万元,收益6.25万元。 以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成 投资建议。 交易信息汇总:8月1日主力资金净流出571.48万元,占总成交额5.0%。 公司公告汇总:奥锐特药业股份有限公司赎回了400 ...
奥锐特: 奥锐特药业股份有限公司关于“奥锐转债”2025年付息公告
Zheng Quan Zhi Xing· 2025-07-21 16:13
Key Points - The company announced the interest payment schedule for its convertible bonds, "Aorite Convertible Bonds," with the interest payment date set for July 28, 2025 [1][6] - The interest accrual period for the bonds is from July 26, 2024, to July 25, 2025, with a coupon rate of 0.3% [3][5] - The bondholders will receive a total interest amount of RMB 0.3 per bond (before tax) for each bond with a face value of RMB 100 [3][5] - The tax on interest income for individual investors is set at 20%, resulting in a net payment of RMB 0.24 per bond after tax [5] - The bond's registration date for interest payment is July 25, 2025, and the ex-dividend date is July 28, 2025 [4][6] - The company has appointed China Securities Depository and Clearing Corporation Limited Shanghai Branch to handle the interest payment process [4][5]
奥锐特: 奥锐特药业股份有限公司关于“奥锐转债”2025年跟踪信用评级结果的公告
Zheng Quan Zhi Xing· 2025-06-27 16:24
Group 1 - The core viewpoint of the announcement is that the credit rating for the company's convertible bonds and the company itself remains unchanged at AA- with a stable outlook [1][2] - The previous credit rating for the convertible bonds was AA- and the company’s main credit rating was also AA- with a stable outlook [1] - The credit rating was conducted by China Chengxin International Credit Rating Co., Ltd. based on a comprehensive analysis of the company's operational status and industry conditions [2] Group 2 - The tracking credit rating report was issued on June 27, 2025, confirming that both the convertible bonds and the company maintain their AA- ratings [2] - The announcement emphasizes that there are no false records, misleading statements, or significant omissions in the content [1]
奥锐特: 奥锐特药业股份有限公司关于因实施权益分派调整“奥锐转债”转股价格的公告
Zheng Quan Zhi Xing· 2025-06-12 10:28
Core Viewpoint - The company announced an adjustment to the conversion price of its convertible bonds due to the implementation of a cash dividend distribution for the fiscal year 2024, resulting in a new conversion price of 24.94 CNY per share, effective from June 20, 2025 [1][4][5] Group 1: Bond Information - The company issued convertible bonds amounting to 812,120,000.00 CNY on July 26, 2024, with a maturity of 6 years and an initial conversion price of 25.23 CNY per share [2][3] - The conversion period for the bonds is from February 5, 2025, to July 25, 2030 [2] Group 2: Dividend Distribution - The company plans to distribute a cash dividend of 2.90 CNY per 10 shares (including tax) to all shareholders, excluding treasury stock [2][3] - The cash dividend per share is calculated to be 0.2890 CNY [5] Group 3: Conversion Price Adjustment - The conversion price adjustment formula is based on the distribution of cash dividends and is calculated as follows: P1 = P0 - D, where P0 is the original conversion price and D is the cash dividend per share [3][5] - The adjusted conversion price is calculated to be 24.94 CNY per share, down from the original price of 25.23 CNY per share [4][5] - The bonds will be suspended from conversion from June 12, 2025, to June 19, 2025, and will resume conversion on June 20, 2025 [1][4]
奥锐特: 奥锐特药业股份有限公司关于调整2024年度利润分配现金分红总额的公告
Zheng Quan Zhi Xing· 2025-06-12 10:16
Summary of Key Points Core Viewpoint - The company has announced an adjustment to the total cash dividend distribution for the fiscal year 2024, reducing it from RMB 117,796,550.00 to RMB 117,401,979.77 due to changes in the number of shares eligible for profit distribution resulting from convertible bond conversions and share buybacks [1][3]. Group 1: Dividend Distribution Adjustment - The total cash dividend amount for 2024 is adjusted to RMB 117,401,979.77 (including tax), maintaining a distribution of RMB 2.90 per 10 shares [1][3]. - The adjustment is necessary due to changes in the total number of shares participating in the profit distribution caused by the conversion of convertible bonds and the company's share buyback program [1][2]. Group 2: Convertible Bonds and Share Buyback - The company has issued convertible bonds, with a conversion period from February 5, 2025, to July 25, 2030, and an initial conversion price of RMB 25.23 per share, resulting in an increase of 234 shares due to conversions [2]. - The company has repurchased a total of 1,360,900 shares since January 1, 2025, with 79 shares used for convertible bond conversions, leaving 1,360,821 shares in the repurchase account, which will not participate in the profit distribution [2].
奥锐特: 奥锐特药业股份有限公司实施2024年度权益分派时“奥锐转债”停止转股的提示性公告
Zheng Quan Zhi Xing· 2025-06-06 08:15
Group 1 - The company will stop the conversion of its convertible bonds "Aorite Convertible Bonds" (bond code: 111021) from June 12, 2025, until the equity distribution registration date due to the 2024 annual equity distribution [1][2] - The company plans to distribute a cash dividend of 2.90 yuan (including tax) for every 10 shares to all shareholders, excluding treasury stock [1][2] - The company will adjust the conversion price of the convertible bonds according to the issuance terms and relevant regulations after the equity distribution [2] Group 2 - The company will announce the implementation of the equity distribution and the adjustment of the convertible bond conversion price on June 13, 2025 [2] - Holders of the convertible bonds can convert their bonds into shares until June 11, 2025, to enjoy the equity distribution [2] - The company will maintain the per-share distribution ratio unchanged, adjusting the total distribution amount if there are changes in the total share capital before the equity distribution registration date [1][2]
奥锐特: 奥锐特药业股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
Zheng Quan Zhi Xing· 2025-06-03 08:17
Group 1 - The company announced a share repurchase plan with a total expected amount between 60 million and 120 million RMB [1][2] - The repurchase will be conducted through centralized bidding and is intended for the conversion of the company's convertible bonds [1][2] - As of May 31, 2025, the company has repurchased a total of 1.3609 million shares, representing 0.34% of the total share capital, with a total expenditure of approximately 27.09 million RMB [2] Group 2 - The repurchase price ranged from 18.83 RMB to 21.00 RMB per share [1][2] - The board of directors approved the repurchase plan with unanimous consent during the twelfth board meeting [1] - The repurchase period is set to last for up to 12 months following the board's approval [1]
4月24日投资提示:港股小盘LOF跌停
集思录· 2025-04-23 14:38
明天161124港股小盘LOF会封死跌停的,而且,后天还会封死跌停,我怀疑最后就是跌到成本附近,大家白忙活。 这让我想起个故事。 上次我去澡堂子洗澡: 牛:老板,你这儿洗澡多少钱? 老板:男浴池10元,女浴池100元。 牛:为什么女浴池那么贵? 老板:你就说想去男浴池还是女浴池? 牛:一听这话,果断交了100块。 兴冲冲进女浴池一看,全是买票进来的男的。。。 被骗过一次长记性了。 但前天我去澡堂子,心里又痒痒了,我想虽然概率很低,但成本不高,万一要是能遇到个女的呢? 最后还是忍不住买了100块钱的票。 风语转债:董事会提议下修 维尔转债:下修到底 赛力医疗:收到证监会湖北监管局行政处罚决定书 | 转债代码 | 转债名称 | 强赎天计数 | 现价 | 转股价值 | 溢价率 | 剩余规模 | 转债占正股 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | (亿元) | 流通市值比 | | 128144 | 利民转债 | 还需0天 | 145.777 | 146.35 | -0.39% | 5.042 | 11.10% | | 1136 ...